Lyso-phosphatidylcholine and outcome of preterm babies with respiratory distress syndrome treated with surfactant.

Abstract

Phosphatidylcholine (PC) is the predominant phospholipid in natural surfactant preparations. A metabolic intermediate, lyso-PC, is potentially injurious to the lungs. In the present study, tracheal aspirates from preterm babies with respiratory distress syndrome treated with surfactant were examined for the presence of lyso-PC to determine if there was any correlation with outcome. Eighteen babies were assigned to receive initially either 100 or 200 mg/kg Curosurf followed by up to three further 100-mg/kg doses if required. Lyso-PC was present in aspirates taken 12-24 h after the last treatment from nine of 11 infants who initially received 200 mg/kg but in only one from seven receiving 100 mg/kg initially, and was dependent on the total dose of phospholipid administered. Three babies in the low-dose group developed bronchopulmonary dysplasia, whereas two in the high-dose group were non-survivors, however we could not correlate the presence of lyso-PC with adverse long-term outcome in this group of preterm infants.

• Authors: M M O'Hare, A M Bingham, C McMaster, W L Halahakoon, J D Corcoran, H L Halliday
• Journal: Early human development (Early Hum Dev) Vol. 49 Issue 2 Pg. 135-41 (Sep 19 1997) ISSN: 0378-3782 [Print] Ireland
• PMID: 9226120 (Publication Type: Journal Article)

Chemical References

• Biological Products
• Lysophosphatidylcholines
• Phospholipids
• Pulmonary Surfactants
• We 201
• poractant alfa

Topics

• Biological Products
• Female
• Humans
• Infant, Newborn
• Infant, Premature
• Lysophosphatidylcholines (administration & dosage, adverse effects, analysis)
• Male
• Phospholipids
• Pulmonary Surfactants (administration & dosage)
• Respiratory Distress Syndrome, Newborn (drug therapy, metabolism, mortality)